| Literature DB >> 29951637 |
A F Engelsman1, S Warhurst2, S Fraser1, D Novakovic2, S B Sidhu1.
Abstract
BACKGROUND: Integrity of the recurrent laryngeal nerve (RLN) and the external branch of the superior laryngeal nerve (EBSLN) can be checked by intraoperative nerve monitoring (IONM) after visualization. The aim of this study was to determine the prevalence and nature of voice dysfunction following thyroid surgery with routine IONM.Entities:
Year: 2018 PMID: 29951637 PMCID: PMC5989980 DOI: 10.1002/bjs5.50
Source DB: PubMed Journal: BJS Open ISSN: 2474-9842
Baseline characteristics of patients and nerves at risk
| No. of patients ( | |
|---|---|
| Age (years) | 54·5 (21–84) |
| Sex ratio (F : M) | 85 : 17 |
| Type of surgery | |
| Total thyroidectomy | 70 (68·6) |
| Hemithyroidectomy | 32 (31·4) |
| Lymph node dissection | 15 (14·7) |
| Indication for surgery | |
| Risk of malignancy | 43 (42·2) |
| Goitre | 43 (42·2) |
| Thyrotoxicosis | 14 (13·7) |
| Other | 2 (2·0) |
| Histopathology | |
| Goitre | 54 (52·9) |
| Thyroiditis | 4 (3·9) |
| Other benign | 22 (21·6) |
| Carcinoma | 22 (21·6) |
Values in parentheses are percentages unless indicated otherwise;
values are median (range).
Baseline characteristics of nerves at risk
| No. of nerves at risk | |||
|---|---|---|---|
| Right side ( | Left side ( | Total ( | |
| EBSLN | |||
| Cernea classification | |||
| Type 1 | 23 (28) | 44 (49) | 67 (39·0) |
| Type 2a | 42 (51) | 27 (30) | 69 (40·1) |
| Type 2b | 10 (12) | 8 (9) | 18 (10·5) |
| Missing | 7 (9) | 11 (12) | 18 (10·5) |
| IONM‐assisted identification | 20 (24) | 20 (22) | 40 (23·3) |
| Loss of signal | 1 (1) | 1 (1) | 2 (1·2) |
| RLN | |||
| IONM‐assisted identification | 0 (0) | 1 (1) | 1 (0·6) |
| Not identified | 0 (0) | 1 (1) | 1 (0·6) |
| Missing | 2 (2) | 2 (2) | 4 (2·3) |
| Loss of signal | 3 (4) | 0 (0) | 3 (1·7) |
Values in parentheses are percentages. EBLSN, external branch of the superior laryngeal nerve; IONM, intraoperative nerve monitoring; RLN, recurrent laryngeal nerve.
Results of the objective patient‐reported outcome according to the Voice Handicap Index‐10 over time
| Voice Handicap Index‐10 score | ||||||
|---|---|---|---|---|---|---|
| Before surgery |
| 1 month |
| 3 months |
| |
| Total thyroidectomy | 0·015 | 0·464 | 0·221 | |||
| No | 5·5 (0–29) | 3·0 (0–29) | 2·0 (0–19) | |||
| Yes | 1·0 (0–21) | 2·0 (0–34) | 1·5 (0–23) | |||
| Lymph node dissection | 0·022 | 0·650 | 0·515 | |||
| No | 2·0 (0–29) | 2·0 (0–34) | 2·0 (0–23) | |||
| Yes | 0·0 (0–5) | 3·0 (0–17) | 1·5 (0–11) | |||
| Loss of signal | 0·456 | 0·538 | 0·888 | |||
| No | 1·0 (0–29) | 2·0 (0–29) | 2·0 (0–23) | |||
| Yes | 2·0 (0–21) | 2·0 (0–34) | 1·0 (0–11) | |||
| Cancer | 0·175 | 0·805 | 0·898 | |||
| No | 2·0 (0–29) | 2·0 (0–34) | 2·0 (0–23) | |||
| Yes | 0·5 (0–13) | 4·0 (0–17) | 2·0 (0–13) | |||
Values are median (range).
Kruskal–Wallis test.
Overall changes in objective outcome measurements over time
| After surgery | |||||
|---|---|---|---|---|---|
|
| Before surgery | 1 month | 3 months |
| |
| MPT (s) | 99 | 17·1(7·1) | 15·2(6·7) | 13·4(7·2) | 0·854 |
|
| 85 | 190·4(51·6) | 194·6(49·8) | 194·4(43·4) | 0·418 |
|
| 82 | 128·9(33·1) | 125·8(38·6) | 128·3(31·1) | 0·782 |
|
| 82 | 515·2(218·9) | 461·3(200·1) | 505·5(202·2) | 0·654 |
| HNR (Hz) | 83 | 20·4(3·7) | 20·3(4·2) | 20·5(3·8) | 0·774 |
| CPP (dB) | 80 | 12·3(0·8) | 12·2(0·8) | 12·3(0·8) | 0·957 |
| CPPS (dB) | 79 | 4·2(0·5) | 4·1(0·5) | 4·2(0·5) | 0·307 |
| VHI‐10 | 99 | 2·0 (0–6) | 2·0 (0–8) | 2·0 (0–6) | 0·326 |
Values are mean(s.d.) unless indicated otherwise;
values are median (i.q.r.). MPT, maximum phonation time; f0, fundamental frequency; HNR, harmonic to noise ratio; CPP, cepstral peak prominence; CPPS, smoothed cepstral peak prominence; VHI, Voice Handicap Index.
Generalized linear mixed model, except
generalized estimating equation.
Objective voice outcome measures for each time point, stratified for type of thyroidectomy (hemithyroidectomy versus total thyroidectomy)
| After surgery | ||||||
|---|---|---|---|---|---|---|
| Total thyroidectomy | Before surgery |
| 1 month |
| 3 months |
|
| MPT (s) | 0·264 | 0·228 | 0·183 | |||
| No | 18·3(7·3) | 16·5(6·2) | 15·0(6·6) | |||
| Yes | 16·6(7·0) | 14·8(7·0) | 12·9(7·5) | |||
|
| 0·274 | 0·865 | 0·312 | |||
| No | 177·5(66·1) | 196·0(57·0) | 187·6(44·6) | |||
| Yes | 190·5(49·6) | 194·1(48·8) | 197·4(41·7) | |||
|
| 0·759 | 0·853 | 0·407 | |||
| No | 128·5(35·7) | 125·4(46·4) | 124·1(34·2) | |||
| Yes | 126·2(33·7) | 126·9(33·6) | 130·0(30·1) | |||
|
| 0·040 | 0·026 | 0·055 | |||
| No | 572·8(250·0) | 524·1(225·8) | 567·0(213·1) | |||
| Yes | 478·2(185·9) | 431·7(193·0) | 479·7(190·8) | |||
| HNR (Hz) | 0·513 | 0·157 | 0·314 | |||
| No | 20·6(2·9) | 19·5(3·9) | 20·0(4·1) | |||
| Yes | 20·0(4·7) | 20·8(4·1) | 20·1(3·8) | |||
| CPP (dB) | 0·311 | 0·797 | 0·506 | |||
| No | 12·1(0·8) | 12·2(0·8) | 12·3(0·7) | |||
| Yes | 12·3(0·8) | 12·2(0·8) | 12·2(0·8) | |||
| CPPS (dB) | 0·222 | 0·510 | 0·722 | |||
| No | 4·1(0·5) | 4·1(0·6) | 4·2(0·6) | |||
| Yes | 4·2(0·6) | 4·2(0·6) | 4·2(0·6) | |||
Values are mean(s.d.). MPT, maximum phonation time; f0, fundamental frequency; HNR, harmonic to noise ratio; CPP, cepstral peak prominence; CPPS, smoothed cepstral peak prominence.
ANOVA.
Objective voice outcome measures for each time point, stratified for lymph node dissection
| After surgery | ||||||
|---|---|---|---|---|---|---|
| Lymph node dissection | Before surgery |
| 1 month |
| 3 months |
|
| MPT (s) | 0·547 | 0·212 | 0·119 | |||
| No | 16·9(6·3) | 15·0(6·3) | 13·1(6·9) | |||
| Yes | 18·2(11·3) | 17·4(9·4) | 16·4(8·7) | |||
|
| 0·836 | 0·350 | 0·957 | |||
| No | 186·8(53·6) | 192·8(51·9) | 194·0(43·2) | |||
| Yes | 183·5(67·4) | 207·2(47·3) | 194·7(41·6) | |||
|
| 0·333 | 0·619 | 0·375 | |||
| No | 128·2(32·3) | 125·7(38·3) | 126·8(31·6) | |||
| Yes | 118·3(45·8) | 131·6(37·6) | 135·9(31·7) | |||
|
| 0·014 | 0·990 | 0·490 | |||
| No | 527·5(211·7) | 462·4(201·5) | 515·5(212·0) | |||
| Yes | 374·0(154·0) | 463·1(123·4) | 470·2(106·5) | |||
| HNR (Hz) | 0·050 | 0·851 | 0·637 | |||
| No | 20·5(4·1) | 20·3(4·1) | 20·6(3·9) | |||
| Yes | 18·1(4·1) | 20·5(3·9) | 20·1(3·1) | |||
| CPP (dB) | 0·778 | 0·514 | 0·771 | |||
| No | 12·2(0·8) | 12·2(0·8) | 12·3(0·8) | |||
| Yes | 12·3(0·9) | 12·1(1·2) | 12·3(1·0) | |||
| CPPS (dB) | 0·930 | 0·711 | 0·987 | |||
| No | 4·2(0·6) | 4·2(0·5) | 4·2(0·6) | |||
| Yes | 4·2(0·6) | 4·1(0·6) | 4·2(0·6) | |||
Values are mean(s.d.). MPT, maximum phonation time; f0, fundamental frequency; HNR, harmonic to noise ratio; CPP, cepstral peak prominence; CPPS, smoothed cepstral peak prominence.
ANOVA.
Objective voice outcome measures for each time point, stratified for intraoperative loss of signal of any nerve
| After surgery | ||||||
|---|---|---|---|---|---|---|
| Loss of signal | Before surgery |
| 1 month |
| 3 months |
|
| MPT (s) | 0·671 | 0·006 | 0·887 | |||
| No | 17·2(7·3) | 15·7(6·6) | 13·6(7·4) | |||
| Yes | 15·8(2·6) | 7·2(6·7) | 13·1(2·1) | |||
|
| 0·894 | 0·570 | 0·694 | |||
| No | 186·2(56·5) | 194·2(51·8) | 194·5(43·6) | |||
| Yes | 189·6(27·5) | 211·4(33·1) | 186·7(25·9) | |||
|
| 0·440 | 0·948 | 0·472 | |||
| No | 126·3(34·6) | 126·5(38·7) | 128·6(31·3) | |||
| Yes | 138·5(26·4) | 125·0(5·9) | 118·1(37·9) | |||
|
| 0·995 | 0·253 | 0·395 | |||
| No | 507·1(215·2) | 466·6(194·6) | 514·4(204·9) | |||
| Yes | 507·7(116·0) | 336·7(49·8) | 434·7(136·2) | |||
| HNR (Hz) | 0·002 | 0·900 | 0·563 | |||
| No | 20·5(3·7) | 20·3(4·0) | 20·5(3·8) | |||
| Yes | 14·5(8·7) | 20·6(6·2) | 21·5(2·1) | |||
| CPP (dB) | 0·172 | 0·110 | 0·039 | |||
| No | 12·3(0·8) | 12·2(0·8) | 12·3(0·8) | |||
| Yes | 11·8(0·8) | 11·4(0·8) | 11·6(1·0) | |||
| CPPS (dB) | 0·173 | 0·448 | 0·039 | |||
| No | 4·2(0·6) | 4·2(0·6) | 4·2(0·5) | |||
| Yes | 3·9(0·6) | 3·9(0·3) | 3·7(1·0) | |||
Values are mean(s.d.). MPT, maximum phonation time; f0, fundamental frequency; HNR, harmonic to noise ratio; CPP, cepstral peak prominence; CPPS, smoothed cepstral peak prominence.
ANOVA.
Objective voice outcome measures for each time point, stratified for histopathology outcome
| After surgery | ||||||
|---|---|---|---|---|---|---|
| Pathology | Before surgery |
| 1 month |
| 3 months |
|
| MPT (s) | 0·234 | 0·197 | 0·178 | |||
| Benign | 16·7(6·1) | 14·9(6·4) | 13·0(6·8) | |||
| Malignant | 18·8(10·1) | 17·0(8·0) | 15·4(8·4) | |||
|
| 0·715 | 0·733 | 0·631 | |||
| Benign | 187·4(54·4) | 193·8(51·9) | 195·2(43·9) | |||
| Malignant | 182·5(59·9) | 198·1(50·4) | 189·9(38·8) | |||
|
| 0·096 | 0·328 | 0·738 | |||
| Benign | 129·9(32·2) | 128·4(36·2) | 128·6(31·8) | |||
| Malignant | 115·9(39·9) | 119·0(44·8) | 125·8(31·1) | |||
|
| 0·067 | 0·944 | 0·842 | |||
| Benign | 527·5(205·8) | 461·8(190·9) | 512·0(217·6) | |||
| Malignant | 432·5(217·7) | 465·2(209·3) | 501·3(129·2) | |||
| HNR (Hz) | 0·243 | 0·614 | 0·283 | |||
| Benign | 20·5(4·1) | 20·4(4·1) | 20·8(3·8) | |||
| Malignant | 19·2(4·4) | 19·9(4·1) | 19·8(3·7) | |||
| CPP (dB) | 0·574 | 0·587 | 0·968 | |||
| Benign | 12·3(0·8) | 12·2(0·8) | 12·3(0·8) | |||
| Malignant | 12·2(0·8) | 12·1(0·9) | 12·3(0·8) | |||
| CPPS (dB) | 0·115 | 0·306 | 0·428 | |||
| Benign | 4·3(0·6) | 4·2(0·6) | 4·2(0·6) | |||
| Malignant | 4·0(0·6) | 4·1(0·6) | 4·2(0·6) | |||
Values are mean(s.d.). MPT, maximum phonation time; f0, fundamental frequency; HNR, harmonic to noise ratio; CPP, cepstral peak prominence; CPPS, smoothed cepstral peak prominence.
ANOVA.